WLWenxin Liu

Wenxin Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenxin Liu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Jindong Sheng

    Department of Gynaecological Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

    3 shared publications
  • Jing Luan

    Department of Gynaecological Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    3 shared publications
  • Chunyan Liu

    Department of Gynaecological Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China

    2 shared publications
  • Lu Sun

    Department of Gynaecological Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    2 shared publications
  • Ruoyan Liu

    Department of Gynaecological Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China

    2 shared publications
  • Xiangyu Liu

    Department of Gynaecological Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    2 shared publications

Latest Publications

  • Open Access

    SFRP2 drives aerobic glycolysis and tumor progression in ovarian cancer by transcriptional upregulation of PTK2B

    by Jindong Sheng, Yiwen Xing, Jing Luan, Xiangyu Liu, Hualin Song, Lu Sun, Min Yu, Xin Fu, Huijuan Wu, Ying Chen, et al.

    Background: Ovarian cancer is a highly lethal gynecologic malignancy, with metabolic reprogramming being a key contributor to its progression and therapeutic resistance. Although Secreted Frizzled-Related Protein 2 (SFRP2) has been implicated in various cancers, its functional role and molecular mechanisms in ovarian cancer, particularly in regulating metabolic pathways, remain poorly defined. Methods: Bioinformatic analyses of GEO (GSE66957) and TCGA-OV datasets were performed to assess SFRP2 expression and its prognostic correlation. Immunohistochemistry (IHC) on a human ovarian cancer tissue microarray was used for clinical validation. SFRP2 was knocked down or overexpressed in ovarian cancer cell lines (HEY and SK-OV-3) using lentiviral shRNA vectors. Functional assays (CCK-8, colony formation, apoptosis, migration) and metabolic assays (glucose consumption, lactate/ATP production, ECAR/OCR) were conducted. The mechanistic link between SFRP2, transcription factor CEBPA, and downstream target PTK2B was investigated using co-immunoprecipitation (Co-IP), nuclear-cytoplasmic fractionation, chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays. Rescue experiments were performed both in vitro and in vivo (xenograft mouse models). Results: SFRP2 was significantly overexpressed in ovarian cancer tissues and cell lines, and high SFRP2 expression correlated with advanced disease and poor patient survival. SFRP2 knockdown suppressed cell proliferation, colony formation, and migration, while promoting apoptosis. Mechanistically, SFRP2 interacted with the transcription factor CEBPA, promoted its nuclear translocation, and enhanced its occupancy at the PTK2B promoter, thereby driving PTK2B transcriptional activation. This SFRP2/CEBPA/PTK2B axis further activates the AKT/mTOR signaling pathway, upregulating key glycolytic enzymes. Importantly, inhibiting glycolysis with 2-DG or knocking down PTK2B effectively reversed the oncogenic effects of SFRP2 both in vitro and in vivo. Conclusion: Our findings identify a novel SFRP2/CEBPA/PTK2B signaling axis that drives aerobic glycolysis and malignant progression in ovarian cancer, highlighting SFRP2 and PTK2B as potential prognostic markers and therapeutic targets.

  • Open Access

    Near-Infrared-Responsive, Oxygen Self-Sufficient Nanoparticles for Combined Photothermal and Thermally Activated Photodynamic Therapy in Oxygen-Deficient Environments

    by Yuanjie Cao, Yunying Zhao, Jing Luan, Yan Lu, Wenxin Liu, Jie Chen, Linlin Zhao

    Hypoxia severely limits the efficacy of photodynamic therapy (PDT) because oxygen shortage suppresses the generation of cytotoxic reactive oxygen species (ROS). Here we report near-infrared (NIR)-responsive, oxygen self-sufficient nanoparticles (TANPs) that integrate photothermal therapy (PTT) with thermally activated, oxygen self-sufficient PDT and are designed to enhance phototherapy performance in oxygen-deficient settings. TANPs were obtained by nanoprecipitation of an A-D-A type photothermal agent (3TT-IC-4Cl) and a thermally activatable endoperoxide (APO) in DSPE-PEG2000. The nanoparticles showed a uniform spherical morphology with an average hydrodynamic diameter of ∼150 nm, strong NIR absorption, and excellent colloidal and photothermal stability. Upon 880 nm irradiation, TANPs generated robust hyperthermia (ΔT > 50 °C at 180 μg/mL) with a photothermal conversion efficiency of 30.96% and simultaneously produced ROS via thermally triggered APO activation. In vitro, TANPs exhibited negligible dark cytotoxicity but marked light-induced cytotoxicity toward HeLa and 293 cells, outperforming single-mode control nanoparticles (TNPs or ANPs). Flow cytometry confirmed that TANPs induced pronounced early and late apoptosis as a result of combined hyperthermia and ROS-mediated damage. These findings suggest that TANPs constitute a promising nanoplatform to boost phototherapeutic efficacy in oxygen-deficient tumor microenvironments.


  • Open Access

    Clonal origins and divergent evolutionary relationships of synchronous multiple malignant neoplasms in gynecology revealed by next-generation sequencing

    by Jindong Sheng, Jing Luan, Yujie Zhao, Yiwen Xing, Wenfeng Cao, Chunyan Liu, Ruoyan Liu, Lu Sun, Wenxin Liu

  • Open Access

    Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study

    by Jindong Sheng, Haitao Luo, Xiangyu Liu, Chunyan Liu, Wenhao Zhou, Yujie Zhao, Ruoyan Liu, Dan Li, Changxiao Xu, Bo Yang, et al.

    The clinical benefit of neoadjuvant immunochemotherapy in locally advanced cervical cancer (LACC) remains unclear. This single-arm, phase II study (Chinese Clinical Trial Registry, ChiCTR2200065392) aimed to evaluate the efficacy and safety of neoadjuvant anti-programmed cell death protein 1 (PD-1) antibody tislelizumab in combination with chemotherapy in treatment-naïve patients with stage IB3/IIA2 LACC. Enrolled patients received tislelizumab (200 mg, every 3 weeks) plus chemotherapy for 3 cycles before radical surgery. The primary endpoint was the pathological complete response (pCR). Secondary endpoints were objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1, disease-free survival, overall survival, and safety. Exploratory endpoints included tissue-based and blood-based biomarkers to identify the biological drivers behind the clinical outcomes. Between November 2022 and March 2024, 30 patients were enrolled. All patients completed 3 cycles of neoadjuvant immunochemotherapy and underwent radical surgery. The pCR was observed in 20 (66.7%) patients, and 4 (13.3%) patients achieved major pathological response (MPR), with an optimal pathological response rate (OPR) of 80.0%. The ORR was 90.0%, with 17 (56.7%) complete responses. Survival data were immature at the median follow-up of 14.7 months (data cutoff, December 31, 2024). Grade 3 treatment-related adverse events (TRAEs) and immune-related AEs occurred in 26.7% and 3.3% of patients, respectively. No treatment-related death occurred. Patients with pCR had significantly higher expression of PD-L1 CPS at baseline, and a strong relationship with immune-related signature (all p < 0.05). Neoadjuvant tislelizumab plus chemotherapy showed promising antitumor efficacy and a well-tolerated safety profile in patients with stage IB3/IIA2 LACC, and might be a potential option in this population.